Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Clinical trial NCT06492291 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06492291
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-05
- Primary completion
- 2028-10-13
- Enrollment
- 3000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.